Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolerogenixX MIC in Living Donor Kidney Transplantation
NCT05365672Phase 2Recruiting
- Sponsor
- TolerogenixX
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MIC-Tx in kidney transplantation, sponsored by TolerogenixX. Started May 2022; status: recruiting.
02
Drugs
MIC-Tx
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT05365672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365672.